🔍

JAGSNPHARM - Jagsonpal Pharma

📊 NSE: JAGSNPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:32

📢 Recent Corporate Announcements

Jagsonpal Pharmaceuticals Releases Q4 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 28 Apr 2026, 06:13 PM

Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q4 FY26 earnings conference call available to the public. The call, which took place on April 28, 2026, at 3:00 P.M., focused on the financial performance for the quarter and fiscal year ending March 2026. This disclosure is part of the company's regulatory compliance under SEBI Listing Obligations. Investors can access the recording via the company's official investor relations website to review management's commentary.

Audio recording of the Q4 FY26 earnings conference call is now accessible online.
The call was held on April 28, 2026, following the release of annual financial results.
The recording provides management insights into the company's performance for the fiscal year 2025-26.
Compliance filing made under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's outlook on the pharmaceutical sector and specific growth drivers for the next fiscal year. Particular attention should be paid to the Q&A session for clarity on margin trends and product pipeline updates.

Jagsonpal Pharma Sets May 4, 2026, as Record Date for ₹40 Crore Buyback at ₹250/Share

🟢 POSITIVE ⭐ 8/10

OTHER 📅 27 Apr 2026, 08:28 PM

Jagsonpal Pharmaceuticals has finalized May 4, 2026, as the record date for its equity share buyback. The company plans to repurchase up to 16,00,000 shares at a fixed price of ₹250 per share. The total size of the buyback is capped at ₹40 crores, representing a return of surplus cash to shareholders. This corporate action is expected to support the stock price and improve return ratios like ROE and EPS.

Record date for buyback eligibility fixed as Monday, May 04, 2026
Buyback price set at ₹250 per equity share of face value ₹2 each
Total buyback size of up to 16,00,000 shares amounting to ₹40 crores
The buyback will be conducted on a proportionate basis through the tender offer route

💡 Investors seeking to participate in the buyback must own the shares before the ex-date to be eligible by the May 4 record date. Evaluate the premium of the ₹250 buyback price against the current market price for potential gains.

Jagsonpal Pharmaceuticals Grants 1.93 Lakh ESOPs at Exercise Price of Rs 159.50

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 27 Apr 2026, 08:18 PM

Jagsonpal Pharmaceuticals has approved the grant of 1,93,000 employee stock options (ESOPs) under its 2022 Plan. These options are exercisable at a price of Rs 159.50 per share, which will eventually convert into equity shares of face value Rs 2 each. The vesting of these options is scheduled in four equal annual tranches, beginning one year from the grant date. This initiative is designed to retain key talent and align employee performance with long-term shareholder interests.

Grant of 1,93,000 employee stock options approved by the Nomination and Remuneration Committee.
Exercise price set at Rs 159.50 per option, convertible to equity shares of Rs 2 face value.
Vesting period structured in 4 equal annual tranches starting from the first anniversary of the grant.
The grant is issued under the Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022.

💡 Investors should note the potential for minor equity dilution over the next four years as these options vest. No immediate action is required as this is a routine management incentive program.

Jagsonpal Pharmaceuticals Recommends 200% Dividend of Rs 4 Per Share for FY26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 27 Apr 2026, 08:05 PM

The Board of Directors of Jagsonpal Pharmaceuticals has recommended a final dividend of Rs 4 per equity share for the financial year ended March 31, 2026. This payout represents 200% of the face value of Rs 2 per share. The dividend is subject to shareholder approval at the company's 47th Annual General Meeting. Specific dates for the record and payment will be announced separately following the board's recommendation.

Recommended dividend of Rs 4 per equity share for the financial year 2025-26
Dividend payout represents 200% of the face value of Rs 2 per share
Final approval pending from shareholders at the upcoming 47th Annual General Meeting
Record date and tentative payment date to be intimated separately to the exchanges

💡 Investors should track the announcement of the record date to ensure they hold shares before that date to qualify for the Rs 4 payout. The high dividend percentage reflects a positive stance on capital distribution to shareholders.

Jagsonpal Pharma Q4 PAT Jumps 31% to ₹88 Mn; Announces ₹40 Cr Buyback & 200% Dividend

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 27 Apr 2026, 07:54 PM

Jagsonpal Pharmaceuticals reported a strong Q4 FY26 with PAT rising 31% YoY to ₹88 Mn, supported by a 10% revenue growth. For the full year FY26, the company achieved a PAT of ₹446 Mn (+19% YoY) and maintained a robust cash balance of ₹191 Cr. The board has approved a ₹40 Cr buyback at ₹250 per share (a significant premium) and a total dividend of 200%, including a special dividend. The company continues to outperform the Indian Pharma Market (IPM) growth rates, particularly through its top 10 brands which constitute 58% of revenue.

Q4 FY26 PAT grew 31% YoY to ₹88 Mn, while annual FY26 PAT rose 19% to ₹446 Mn.
Approved a ₹40 Cr buyback of 16 lakh shares at ₹250/share, representing a ~40% premium to the announcement date price.
Recommended a 200% dividend (₹4 per share), including a 75% special dividend, with a total payout of ₹26.2 Cr.
Cash and cash equivalents stood at ₹191 Cr as of March 31, 2026, up by ₹45.1 Cr during the year.
Outperformed the Indian Pharma Market (IPM) with 12.2% growth compared to 8.6% market growth on a MAT basis.

💡 Investors should consider the aggressive buyback and special dividend as strong indicators of management's confidence in cash flow and capital efficiency. The company's debt-free status and market outperformance make it a compelling growth-and-income play in the mid-cap pharma space.

Jagsonpal Pharma Q4 PAT Jumps 31%; Announces ₹40 Cr Buyback and 200% Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 27 Apr 2026, 07:52 PM

Jagsonpal Pharmaceuticals reported a strong performance for Q4 FY26, with PAT rising 31% YoY to ₹88 Mn and revenue growing 9.6% to ₹642 Mn. For the full year FY26, the company achieved a PAT of ₹446 Mn (up 19%) and maintained a robust cash balance of ₹191 Cr. The board has approved a ₹40 Cr share buyback at ₹250 per share and a total dividend of 200%, including a special dividend. The company's growth continues to outpace the Indian Pharmaceutical Market (IPM), driven by its top 10 brands which contribute 58% of total revenue.

Q4 FY26 PAT increased by 31% YoY to ₹88 Mn, while full-year PAT grew 19% to ₹446 Mn.
Approved a ₹40 Cr buyback of 16 lakh shares at ₹250 each, representing a significant premium to the market price.
Recommended a 200% total dividend (₹4 per share), including a 75% special dividend, with a total outlay of ₹26.2 Cr.
Cash and cash equivalents stood at a strong ₹191 Cr as of March 31, 2026, up from ₹146 Cr YoY.
Outperformed the Indian Pharmaceutical Market with 12.2% growth compared to the industry's 8.6%.

💡 Investors should view the aggressive capital return via buyback and special dividends as a sign of management's confidence in future cash flows. The company's debt-free status and projected improvement in ROCE to 25.7% post-buyback make it a strong candidate for long-term portfolios.

Jagsonpal Pharma Recommends Rs 4 Dividend; FY26 Revenue Grows 7% to Rs 2,872 Million

🟡 NEUTRAL ⭐ 7/10

DIVIDEND 📅 27 Apr 2026, 07:49 PM

Jagsonpal Pharmaceuticals has recommended a final dividend of Rs. 4 per share (200% of face value) for the financial year ended March 31, 2026. The company's annual revenue from operations increased by 6.9% to Rs. 2,872.25 million compared to the previous year. Despite revenue growth, the annual net profit saw a decline to Rs. 430.82 million from Rs. 553.61 million in FY25. However, Q4 performance was stronger with net profit rising to Rs. 87.62 million from Rs. 65.83 million year-on-year.

Recommended a final dividend of Rs. 4 per equity share (200% of face value Rs. 2)
Annual revenue from operations increased to Rs. 2,872.25 million from Rs. 2,687.16 million
Full-year net profit declined to Rs. 430.82 million compared to Rs. 553.61 million in FY25
Q4 FY26 net profit grew to Rs. 87.62 million versus Rs. 65.83 million in Q4 FY25
Annual Earnings Per Share (EPS) stood at Rs. 6.40, down from Rs. 8.26 in the previous year

💡 The dividend provides a decent yield, but the decline in annual profitability warrants caution. Investors should watch for margin recovery in upcoming quarters as indicated by the improved Q4 results.

Jagsonpal Pharma FY26 Revenue Up 7% to ₹2,872 Mn; Recommends 200% Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 27 Apr 2026, 07:46 PM

Jagsonpal Pharmaceuticals reported a steady operational performance for the financial year ended March 31, 2026, with revenue from operations growing 7% YoY to ₹2,872.25 million. While the net profit for FY26 stood at ₹430.82 million compared to ₹553.61 million in FY25, the prior year's profit was significantly inflated by an exceptional gain of ₹196.87 million. On an operational basis, the profit before exceptional items and tax grew by 18.8% YoY to ₹595.97 million. The company has also announced a substantial dividend of ₹4 per share, representing a 200% payout on face value.

Revenue from operations for FY26 increased to ₹2,872.25 million from ₹2,687.16 million in the previous year.
Profit before exceptional items and tax grew 18.8% YoY to ₹595.97 million, indicating strong core operational efficiency.
Q4 FY26 net profit rose to ₹87.62 million, a 33% increase compared to ₹65.83 million in Q4 FY25.
The Board recommended a final dividend of ₹4 per equity share (200% of face value of ₹2).
Earnings Per Share (EPS) for FY26 stood at ₹6.40, compared to ₹8.26 in FY25 (which included exceptional gains).

💡 Investors should look past the headline PAT decline as it was due to a high base effect from exceptional items last year; the core operational growth remains robust. The high dividend yield and improved quarterly margins make this a positive update for long-term holders.

Jagsonpal Pharmaceuticals Shareholders Approve Rs 40 Crore Buyback at Rs 250 Per Share

🟢 POSITIVE ⭐ 8/10

OTHER 📅 27 Apr 2026, 07:44 AM

Jagsonpal Pharmaceuticals has received shareholder approval for a buyback of up to 16 lakh equity shares. The buyback is priced at Rs 250 per share, representing a total capital outlay of up to Rs 40 crore. This corporate action is designed to optimize the company's capital structure and improve Earnings Per Share (EPS). The company will communicate the specific timelines and record date for the buyback in due course.

Shareholders approved the buyback of up to 16,00,000 equity shares.
The buyback price is fixed at Rs 250 per share, totaling up to Rs 40 crore.
The proposal was originally recommended by the Board on March 12, 2026.
The initiative aims to enhance shareholder value and optimize capital allocation.
Timelines and record date for the offer are yet to be announced.

💡 Investors should watch for the announcement of the record date to determine eligibility for the buyback. The Rs 250 price offers a potential exit or arbitrage opportunity depending on the current market price.

Jagsonpal Pharma Shareholders Approve ₹40 Crore Share Buyback at ₹250 Per Share

🟢 POSITIVE ⭐ 7/10

OTHER 📅 27 Apr 2026, 07:23 AM

Jagsonpal Pharmaceuticals has received shareholder approval via postal ballot for a significant share buyback program. The company will repurchase up to 16,00,000 equity shares at a fixed price of ₹250 per share, involving a total outlay of ₹40 crores. The resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor of the proposal. This move is designed to return surplus cash to shareholders and optimize the company's capital structure.

Approved buyback of up to 16,00,000 fully paid-up equity shares.
Buyback price set at ₹250 per share for equity shares with a face value of ₹2.
Total aggregate amount for the buyback is capped at ₹40 crores.
Resolution passed with 99.994% majority (4,89,18,088 votes in favor).
The buyback was conducted through a postal ballot process ending April 24, 2026.

💡 Investors should monitor the announcement of the record date to determine eligibility for the buyback. The offer price of ₹250 may offer an attractive premium depending on the prevailing market price.

Jagsonpal Pharmaceuticals to Host Q4 FY26 Earnings Call on April 28, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 22 Apr 2026, 04:23 PM

Jagsonpal Pharmaceuticals has scheduled its Q4 FY26 earnings conference call for April 28, 2026, at 3:00 PM IST. The company's top management, including the Managing Director, CFO, and COO, will be present to discuss the financial performance for the quarter and the full fiscal year. This call is a routine but essential event for investors to understand the company's growth trajectory and operational efficiency. The session will be hosted by Go India Advisors and includes a dedicated Q&A session.

Earnings conference call scheduled for Tuesday, April 28, 2026, at 3:00 PM IST.
Management to discuss financial results for Q4 FY26 and the full year FY26.
Key participants include MD Manish Gupta, CFO Nirav Vora, and COO Amrut Medhekar.
Universal dial-in numbers provided are +91 22 6280 1557 and +91 22 7115 8383.

💡 Investors should participate in the call to seek clarity on the company's margin outlook and product pipeline for FY27. Monitor the management's commentary on any strategic shifts or expansion plans discussed during the session.

Jagsonpal Pharmaceuticals Allots 1.76 Lakh Equity Shares Under ESOP 2022

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Apr 2026, 04:37 PM

Jagsonpal Pharmaceuticals has allotted 1,76,900 equity shares to eligible employees following the exercise of options under its 2022 ESOP scheme. This allotment has increased the company's paid-up share capital from Rs. 13.39 crore to Rs. 13.43 crore. The shares were issued at exercise prices ranging from Rs. 94.00 to Rs. 115.60 per share. The dilution to existing shareholders is marginal, representing approximately 0.26% of the post-allotment capital.

Allotment of 1,76,900 equity shares of face value Rs. 2 each upon exercise of vested options.
Total paid-up equity shares increased from 6,69,62,250 to 6,71,39,150.
Exercise prices set at Rs. 94.00 (1,57,500 shares), Rs. 113.60 (19,000 shares), and Rs. 115.60 (400 shares).
Paid-up share capital rose from Rs. 13,39,24,500 to Rs. 13,42,78,300.
The newly allotted shares rank pari-passu with existing equity shares.

💡 This is a routine corporate action with minimal impact on the company's valuation. No specific action is required from investors.

Jagsonpal Pharmaceuticals Submits SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Apr 2026, 04:48 PM

Jagsonpal Pharmaceuticals Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MCS Share Transfer Agent Limited, covers the quarter ended March 31, 2026. It confirms that physical share certificates received for dematerialization were processed, mutilated, and cancelled within the required 15-day period. This is a standard regulatory filing ensuring the integrity of the company's shareholding records.

Compliance certificate submitted for the quarter ended March 31, 2026.
Confirms dematerialization requests were processed within the mandatory 15-day timeframe.
Registrar MCS Share Transfer Agent Limited verified the cancellation of physical certificates.
The depository's name has been substituted in the records as the registered owner for dematerialized shares.

💡 No action is required as this is a routine administrative disclosure. Investors should continue to monitor the company's upcoming quarterly financial results for material performance indicators.

Jagsonpal Pharmaceuticals Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Mar 2026, 04:30 PM

Jagsonpal Pharmaceuticals Limited has announced the closure of its trading window for designated persons starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The closure pertains to the audited financial results for the quarter and full financial year ending March 31, 2026. The trading window will reopen 48 hours after the financial results are officially declared to the exchanges.

Trading window closure effective from Wednesday, April 1, 2026.
Closure is related to the audited financial results for the quarter and year ending March 31, 2026.
Trading window will reopen 48 hours after the declaration of financial results.
Restriction applies to all Designated Persons and their immediate relatives.
The specific date for the Board Meeting to approve results will be announced separately.

💡 This is a routine regulatory announcement with no direct impact on business fundamentals. Investors should monitor for the upcoming board meeting date to review the company's full-year financial performance.

Jagsonpal Pharma Announces Buyback of 16 Lakh Shares at ₹250 Per Share via Tender Offer

🟢 POSITIVE ⭐ 8/10

OTHER 📅 25 Mar 2026, 04:59 PM

Jagsonpal Pharmaceuticals has initiated a postal ballot to seek shareholder approval for a buyback of up to 16,00,000 equity shares at ₹250 per share. The total buyback size is capped at ₹40 crores, representing 18.35% of the company's paid-up capital and free reserves as of March 2025. Crucially, promoters and the promoter group are excluded from this offer, which will be conducted via the tender offer route. The e-voting period for shareholders is scheduled from March 26, 2026, to April 24, 2026.

Buyback of up to 16,00,000 equity shares (2.39% of total shares) at a price of ₹250 per share.
Total buyback size is ₹40 crores, which is 18.35% of the aggregate paid-up capital and free reserves.
The offer is via the Tender Offer route, ensuring a proportionate exit for participating shareholders.
Promoters and promoter group are specifically excluded from participating in the buyback.
15% of the buyback is reserved for small shareholders as per SEBI regulations, potentially increasing their acceptance ratio.

💡 Investors should compare the current market price with the ₹250 buyback price to assess the premium and potential arbitrage. Small shareholders should consider tendering their shares to benefit from the 15% reservation quota.

View All JAGSNPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue for H1 FY26 reached INR 150.1 Cr, a 10.2% YoY increase. Q2 FY26 revenue was INR 74.5 Cr, a marginal 0.3% YoY decline due to GST 2.0 transition adjustments. Key segments include Gynaecology, Orthopaedics, Dermatology, and Child-care, with Dydrogesterone growing from zero to INR 40 Cr within 18 months of launch.

Geographic Revenue Split

The company maintains an extensive pan-India distribution network; however, specific percentage splits by region are not disclosed in the available documents.

Profitability Margins

Net Profit Ratio improved significantly to 20.6% in FY 2024-25 from 10.8% in FY 2023-24. Q2 FY26 PAT margin expanded by 154 bps YoY to 16.9%, driven by improved business performance and operational efficiencies post-acquisition of Yash Pharma.

EBITDA Margin

Operating EBITDA margin (pre-ESOP) for Q2 FY26 stood at 24.3%, a slight 39 bps decline from 24.6% YoY. H1 FY26 Operating EBITDA grew 8.8% YoY to INR 33.8 Cr, reflecting efficient cost management and the successful integration of Yash Pharma's profitability to JPL levels.

Capital Expenditure

The company follows an asset-light model with minimal capital expenditure plans as it has transitioned to complete outsourcing of manufacturing operations to contract manufacturers.

Credit Rating & Borrowing

Long-term rating reaffirmed at [ICRA]BBB(Positive) and short-term rating upgraded to [ICRA]A2. The company maintains a robust financial risk profile with nil debt and a strong cash balance of INR 160.4 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed; however, the company procures and supplies raw materials to a pool of contract manufacturers to maintain strict control over product quality.

Key Suppliers

The company utilizes a pool of third-party contract manufacturers rather than owning manufacturing plants, though specific vendor names are not listed.

Capacity Expansion

Current strategy focuses on 'complete outsourcing of manufacturing operations,' eliminating the need for owned capacity expansion. Growth is driven by brand acquisitions and new product launches rather than physical plant expansion.

Raw Material Costs

Raw material costs are managed by supplying inputs to contract manufacturers to mitigate quality risks. Trade payables increased in FY 2024-25 specifically due to the Yash Pharma business acquisition.

Manufacturing Efficiency

Efficiency is driven by an asset-light model. Inventory Turnover Ratio increased to 17.6 in FY 2024-25 from 13.9 in FY 2023-24, reflecting better inventory planning and control.

Logistics & Distribution

The company operates an extensive pan-India distribution network. Current Ratio decreased to 6.2 in FY 2024-25 from 9.5 in FY 2023-24 as surplus funds were utilized for the Yash Pharma acquisition.

📈 Strategic Growth

Expected Growth Rate

10.20%

Growth Strategy

Growth is targeted through a three-pronged strategy: 1) New product launches (e.g., Dydrogesterone), 2) Strategic acquisitions like Yash Pharma to expand the portfolio, and 3) Improving Medical Representative (MR) productivity to drive higher accretive value from existing fixed costs.

Products & Services

Pharmaceutical formulations in the form of medicines for Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Brand Portfolio

Divatrone, Maintane, J.P. Tone, Indocap, and Dydrogesterone.

New Products/Services

New product launches are a core driver; Dydrogesterone contributed ~15% of revenue (approx INR 40 Cr) within 18 months of its FY2022 launch.

Market Expansion

Expansion is focused on the Indian Pharmaceutical Market (IPM), which grew at 7.5% in Q2 FY26. JPL aims to outpace market growth through its 'double-engine' leadership and expanded portfolio.

Market Share & Ranking

Not disclosed as a specific percentage, but identified as a leading player with a 50+ year legacy in specialized segments like Gynaecology.

Strategic Alliances

The company acquired brands from Yash Pharma Private Limited (YPPL) in Q1 FY2025 for an estimated INR 93 Cr to strengthen its market position.

🌍 External Factors

Industry Trends

The Indian pharma market is growing at ~7.5%, driven by price increases. Trends show a shift toward high-margin products and increased regulatory scrutiny on manufacturing standards.

Competitive Landscape

Intense competition from contract manufacturers, MNCs, and established domestic brands, particularly affecting legacy brands like Divatrone and Maintane.

Competitive Moat

Moat is built on a 50-year brand legacy, a robust portfolio in niche segments (Gynaecology), and a strong pan-India distribution network. Sustainability is supported by an asset-light, high-liquidity financial model.

Macro Economic Sensitivity

Sensitive to Indian Pharmaceutical Market (IPM) trends and government healthcare policies like GST 2.0, which aims for affordable healthcare.

Consumer Behavior

Shift toward 'Patient First' approaches and affordable healthcare, influenced by government price reductions passed through GST 2.0.

Geopolitical Risks

The industry faces general regulatory trends and macro-economic condition changes, though JPL's focus is primarily domestic.

⚖️ Regulatory & Governance

Industry Regulations

Approximately 6-7% of revenues are subject to price control. The company must also comply with Ind AS and the Companies Act, 2013.

Taxation Policy Impact

The company transitioned to GST 2.0 in Q2 FY26, passing on price reduction benefits to patients, which caused a temporary moderation in sales.

Legal Contingencies

No material lapses or fraud were reported by internal auditors. The company has a 'Jagsonpal Pharmaceuticals Limited ESOP Plan 2022' in compliance with SEBI SBEBS Regulations.